Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients

ZG Dessie, T Zewotir - BMC infectious diseases, 2021 - Springer
Background Mortality rates of coronavirus disease-2019 (COVID-19) continue to rise across
the world. The impact of several risk factors on coronavirus mortality has been previously …

Systemic immunity in cancer

KJ Hiam-Galvez, BM Allen, MH Spitzer - Nature reviews cancer, 2021 - nature.com
Immunotherapy has revolutionized cancer treatment, but efficacy remains limited in most
clinical settings. Cancer is a systemic disease that induces many functional and …

Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis …

JM Kocarnik, K Compton, FE Dean, W Fu… - JAMA …, 2022 - jamanetwork.com
Importance The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD
2019) provided systematic estimates of incidence, morbidity, and mortality to inform local …

Predictors of COVID‐19 severity: a literature review

B Gallo Marin, G Aghagoli, K Lavine… - Reviews in medical …, 2021 - Wiley Online Library
Summary The coronavirus disease 2019 (COVID‐19) pandemic is a rapidly evolving global
emergency that continues to strain healthcare systems. Emerging research describes a …

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

A Vijenthira, IY Gong, TA Fox, S Booth… - Blood, The Journal …, 2020 - ashpublications.org
Outcomes for patients with hematologic malignancy infected with COVID-19 have not been
aggregated. The objective of this study was to perform a systematic review and meta …

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

LYW Lee, JB Cazier, T Starkey, SEW Briggs… - The Lancet …, 2020 - thelancet.com
Background Patients with cancer are purported to have poor COVID-19 outcomes. However,
cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour …

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

EM Bange, NA Han, P Wileyto, JY Kim, S Gouma… - Nature medicine, 2021 - nature.com
Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the
immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 …

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort …

F Passamonti, C Cattaneo, L Arcaini, R Bruna… - The Lancet …, 2020 - thelancet.com
Background Several small studies on patients with COVID-19 and haematological
malignancies are available showing a high mortality in this population. The Italian …

COVID-19 in immunocompromised hosts: what we know so far

M Fung, JM Babik - Clinical Infectious Diseases, 2021 - academic.oup.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant morbidity and …

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

L Pagano, J Salmanton-García, F Marchesi… - Journal of hematology & …, 2021 - Springer
Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …